25+ years of clinical use
May help mitigate risk of MARCE in comorbid patients4
Improved patient care
Iso-osmolar to blood to minimize vascular fluid shift
Isotonic to blood
Minimizing impact of differences in osmotic pressure.43
Helps reduce costs
Lower hospitalization costs due to shortened length of stay5
India is home to more than 70 million people with diabetes and expected to reach 125 million by 2045.44Diabetic patients undergoing percutaneous transluminal coronary angioplasty (PTCA) are more prone to develop contrast-induced nephropathy (CIN) than non-diabetic.45
Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in high risk patients should be considered to help mitigate the risk of adverse events.9 Visipaque, an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures, was prepared with this in mind. 3
Interventional, structural, or endovascular procedures (e.g., TAVI, CTO, PCI) may need to use higher volumes of iodinated CM. Reducing the frequency of adverse reactions has therefore been a driving force in the development of these diagnostic agents since their initial introduction.9,10
Visipaque is a third-generation agent with a unique molecular structure developed to further improve the safety profile of iodinated contrast agents.3,11 It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.3,12 It is also formulated with balanced electrolytes to help minimize effects on cardiac contractile force/fibrillatory propensity.3,12
While 'low' osmolar agents form the mainstay in the general population of patients undergoing endovascular diagnostic or interventional procedures, Visipaque may be preferred for more complex procedures in patients considered at high risk for cardiovascular or renal insult.4,11
In a real-world study of over half a million co-morbid patients, undergoing IA interventional procedures, Visipaque was associated with a significantly lower absolute risk of MARCE compared to LOCMs.2
When compared to total interventional procedure cost, contrast media is inexpensive but CI-AKI and contrast media-related adverse events may increase the use of health care resources and cost of care.13 Given the growth of vulnerable patient populations, practices that reduce CI-AKI incidence and its associated costs are important to identify.5
According to a study conducted to determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the US, moving on to an IOCM-only strategy may yield substantial cost savings to US hospitals where coronary and peripheral procedures are performed.5
In an European study, whose aim was to assess the financial consequences of CI-AKI risk reduction in patients undergoing coronary angiography, with or without PCI, use of Visipaque brought overall savings on the hospital budget in all four countries.14
Randomized controlled trials often do not address all the clinical scenarios that confront physicians.15,16 Specifically in interventional cardiology, high-risk patients are often routinely excluded from revascularization randomized controlled trials (RCTs).18,19 Real-world data complement traditional clinical trials, with broader populations and health care delivery that reflects actual clinical practice.19
In the interventional cardiology setting, use of iso-osmolar Visipaque is supported by:
• Robust randomized controlled trials20-23
• Meta-analyses of intra-arterial studies24-26
• Real-world data from the cath-lab2
This evidence has shown:
• Visipaque can help reduce major adverse cardiac and renal events (MARCE) in high-risk patients 1,2,24-25
• Intra-arterial use of Visipaque reduced the risk of CI-AKI compared with LOCM by 54%24
• Several large RCTs have shown that Visipaque is associated with significantly fewer cardiac adverse events (such as cardiac death, stroke and coronary artery bypass graft) than LOCM24,25
Patient comfort is important in busy interventional radiology suites. Sensation of heat/pain may lead to patient movement, poor image quality and repeat examinations, creating increased radiation and costs27,28
Visipaque has been shown to significantly reduce discomfort, heat and/or pain, compared to LOCM as well as reducing the risk of major cardiac and renal events.29-33
A study of 26,993 high risk patients undergoing complex revascularisation procedures using real-world data generated in US hospitals, Visipaque reduced the relative risk of MARCE by 24% for patients with CLI (p=0.0022) and by 25% for those with claudication (p<0.0001) versus LOCM.1 This real-world evidence is consistent with meta-analysis of head-to-head RCTS.24,25
Contrast-enhanced CT is important to every step of a cancer patient’s journey, from diagnosis and staging to monitoring and follow-up.34 Cancer patients may be susceptible to the adverse renal effects of iodinated CM as they are exposed to multiple nephrotoxic insults, predisposed to dehydration and require many CT scans.34-36 CI-AKI and CKD are highly prevalent.37
Visipaque can help cancer patients by:
• delivering diagnostic accuracy through enabling valuable contract-enhanced CT in patients with renal impairment38
• addressing renal complications considering vulnerable patients with multiple risk factors38-40
• minimising contrast-associated pain protecting patient comfort and care41-42
Please click here for Visipaque prescribing information
Access the Adverse Event Form Here
Adverse events should also be reported to GE Healthcare at:
IndiaAdverse.events@ge.com
Learn more about supporting resources for contrast media?
PCI in elderly patients
Is age alone enough reason to avoid percutaneous coronary intervention (PCI) in elderly patients?
Looking for medical information?
Our Smart Assistant makes reading medical information easier than ever. With clearly defined sections and navigation, you can easily find the information you need without having to navigate lengthy documents.
You are now leaving a GE commercial site and being re-routed to a medical affairs site. GE healthcare does not recommend or endorse the use of its products outside of the FDA approved full Prescribing Information. Further, the information contained here should not be considered medical advice or guidelines and is intended to be nonpromotional. This information is for a US audience only. It is not intended to replace individual medical judgement or consultation with an appropriate medical professional.
Kidneys and contrast media
What makes the kidneys especially prone to injury from iodinated contrast media?
Educational programs
Webinar: Acute Kidney Injury - Complications in the Cardiac Cath Lab
Contrast-associated acute kidney injury (CA-AKI) is a challenge that may be encountered in the cardiac catheterization lab. In this on-demand webinar, Dr. Arnold Seto, Cardiac Cath Lab Director, Long Beach VA, and Director of Interventional Cardiology Research at University of California, Irvine, discusses the increasing incidence with comorbidities and complex procedures. He talks about the implications of AKI as well as mitigation strategies. Dr. Seto also shares emerging data on AKI in COVID-19 patients.
Watch now
Interventional cardiology and TAVI
Operating at the limits of interventional Cardiology: transcatheter aortic valve implantation (TAVI)
